[Correspondence] Targeted-release budesonide therapy for IgA nephropathy

Bengt Fellstr öm and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5–1·0 g/day , as were enrolled in this study, need further treatments in addition to RAS blockade therapy remains debatable.2,3 The 2012 Kidney Disease Improving Global Outcome guidelines4 suggest giving corticosteroids to patients with persistent proteinuria of more than 1 g/day who do not respond to optimised RAS blockade treatment.
Source: LANCET - Category: General Medicine Authors: Tags: Correspondence Source Type: research